It's hard not to get excited about this company's experimental gene therapy for Duchenne muscular dystrophy.
News & Analysis: Sarepta Therapeutics
These stocks took larger hits than the overall market. Find out why.
SRPT earnings call for the period ending December 31, 2018.
Here's why Viking Therapeutics, Cambrex, and Sarepta Therapeutics are all solid biotech plays this month.
Here's why a competitor's pain was Sarepta's gain recently.
Clinical trial readouts on the way will move these stocks before 2019's finished.
Here's what you need to know about the FDA's latest plans to meet the biotech industry halfway.
Clinical-trial and regulatory-review decisions make these three drug developers worth keeping tabs on this year.
A competitive threat is advancing, but investors might want to view last month's pullback as an opportunity.
Lifting of a clinical hold continued the momentum.